Search

Displaying results 5601 - 5610 of 7540 in total
  1. Drug

    Daplusiran

    go.drugbank.com/drugs/DB19331
    Investigational

    Daplusiran is under investigation in clinical trial NCT06537414 (A Study of Sequential Therapy With Daplusiran/tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis

  2. Drug

    Lumretuzumab

    go.drugbank.com/drugs/DB12683
    Investigational

    Lumretuzumab has been used in trials studying the treatment of Neoplasms, Breast Cancer, Squamous Non-Small Cell Lung Cancer, and Non-Squamous Non-Small Cell Lung Cancer.

  3. Drug

    Nifenazone

    go.drugbank.com/drugs/DB13407
    Experimental

    Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDS
  4. Drug

    Proglumetacin

    go.drugbank.com/drugs/DB13527
    Investigational

    Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDS
  5. Drug

    Mofebutazone

    go.drugbank.com/drugs/DB13629
    Experimental

    Categories: Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Non-Steroidal
  6. Drug

    Andrographolide

    go.drugbank.com/drugs/DB05767
    Investigational

    Andrographolide (HMPL-004) is a botanical product extracted from a herb that occurs naturally in China. The herb has an extensive history of use in TCM for the treatment of upper respiratory tract infections and other inflammatory and in...

    Categories: Analgesics, Non-Narcotic
  7. Drug

    ASP-8731

    go.drugbank.com/drugs/DB17696
    Investigational

    Developed by Mitobridge, it is being investigated for the treatment of sickle cell disease.[L46093]

  8. Drug

    Bacteroides thetaiotaomicron

    go.drugbank.com/drugs/DB17879
    Investigational

    Developed by 4D Pharma, Thetanix, an oral formulation comprising lyophilized Bacteroides thetaiotaomicron, is being investigated for the treatment of Crohn’s disease.[A259892]

  9. Drug

    ALS-08

    go.drugbank.com/drugs/DB05705
    Experimental

    It is being developed by Avicena Group, Inc.

  10. Drug

    Otamixaban

    go.drugbank.com/drugs/DB06635
    Investigational

    It is currently being developed by the French pharmaceutical company Sanofi-Aventis as a treatment for acute coronary syndrome.